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Abstract A phase I/II study was conducted to test the
feasibility and safety of the adoptive transfer of tumor-
reactive T cells and daily injections of interferon-alpha
(IFN) in metastatic melanoma patients with progressive
disease. Autologous melanoma cell lines were established
to generate tumor-speciWc T cells by autologous mixed
lymphocyte tumor cell cultures using peripheral blood
lymphocytes. Ten patients were treated with on average
259 (range 38–474) million T cells per infusion to a maxi-
mum of six infusions, and clinical response was evaluated
according to the response evaluation criteria in solid
tumors (RECIST). Five patients showed clinical beneWt
from this treatment, including one complete regression,
one partial response, and three patients with stable dis-
ease. No treatment-related serious adverse events were
observed, except for the appearance of necrotic-like
Wngertips in one patient. An IFN-related transient leuco-
penia was detected in 6 patients, including all responders.
One responding patient displayed vitiligo. The infused T-
cell batches consisted of tumor-reactive polyclonal CD8+
and/or CD4+ T cells. Clinical reactivity correlated with
the functional properties of the infused tumor-speciWc T
cells, including their in vitro expansion rate and the secre-
tion of mainly Th1 cytokines as opposed to Th2 cyto-
kines. Our study shows that relatively low doses of T cells
and low-dose IFN can lead to successful treatment of
metastatic melanoma and reveals a number of parameters
potentially associated with this success.
Keywords Adoptive cell transfer · Melanoma · 
Tumor-speciWc T cells · IFN-alpha
Introduction
Melanoma has long been acknowledged to be a susceptible
target for immunotherapy. A high number of melanomas
are inWltrated by T cells, and the strength, phenotype, and
activation status of inWltrated cells are associated with sur-
vival [1].
Adoptive cell transfer (ACT), i.e., the infusion of ex vivo
expanded tumor-speciWc T cells, resulted in objective
tumor responses in melanoma patients [2]. Previous ACT
trials have demonstrated that clinical success required
lymphodepletion prior to T-cell infusion and concomitant
administration of high-dose interleukin-2 (IL-2) to maintain
cell proliferation and activation status [3].
In allogeneic stem cell transplantation, interferon-alpha
(IFN) is routinely used to replace the far more toxic IL-2
to sustain the activation status of infused donor cells [4]. In
addition, IFN displays the capacity to upregulate HLA
class I expression on tumor cells [5]. These molecules are
critical for tumor cell recognition by T cells and often (par-
tially) downregulated in melanoma [6]. Furthermore, IFN
is described to drive DC maturation required for generation
of tumor-speciWc eVector- and central-memory CD8+ T
cells [7, 8].
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Therefore, we studied the feasibility and potential of
ACT in combination with IFN for the treatment of meta-
static melanoma. Tumor-reactive T cells were obtained
from PBMC, as highly eVective melanoma reactive CTL
are readily induced from PBMC [9, 10] following stimula-
tion with autologous tumor cells established from tumor
biopsies.
Patients and methods
Melanoma patients
Patients with histologically proven cutaneous melanoma
with veriWed progressive metastatic disease stage IV or
unresectable stage III refractory to treatment before the
start of the study and with at least one measurable target
lesion were eligible for this phase I/II study. The protocol
was approved by the Medical Ethics Committee of the
Leiden University Medical Center and conducted in
accordance with the Declaration of Helsinki. All patients
gave written informed consent. Patients with brain metas-
tases who are neurologically unstable and/or require use
of dexamethasone and patients who are on continued
chemo- or radiotherapy until 4 weeks before the start of
IFN injections were excluded from the study. The pri-
mary objective of this study was to investigate the feasi-
bility and safety of adoptive T-cell transfer in
combination with IFN. Secondary endpoints include the
best overall response deWned as disease control (CR, PR,
and SD) and evaluation of immunological parameters as
predictors for response.
Treatment protocol
Patients received T cells as three consecutive infusions
of on average 259 (range 38–474) million cells with a
3-week interval in combination with low-dose IFN
(3 million IU Roferon, Roche, Woerden, The Nether-
lands, subcutaneously daily) starting at day 7 before the
Wrst T-cell infusion and for a total of 12 weeks. Cryopre-
served T cells were thawed and diluted to a total volume
of 300 ml in PBS/2% human serum albumin (Albuman,
Sanquin, Amsterdam, the Netherlands) and a Wnal concen-
tration of less than 1% DMSO. Then, the cells
were administered intravenously over a time period of
30–60 min. At various time points before, during and
after treatment, the tumor response was assessed by phys-
ical examination and tumor imaging (CT and MRI) and
evaluated according to the Response Evaluation Criteria
in Solid Tumors 1.0 (RECIST) [11] and according to the
immune-related response criteria (irRC) [12]. Toxicity
was scored using the CTC scale version 3.0.
Establishment of GMP-grade primary melanoma lines
Autologous melanoma cell lines were initiated and cultured
using authorized Standard Operating Procedures (SOPs).
Tumor tissue obtained by surgery was directly processed by
mechanical dissociation and cultured in tumor medium
consisting of Dulbecco’s MEM (DMEM, Lonza, Veriers,
Belgium) supplemented with 8% irradiated, heat-inacti-
vated GMP-grade pre-tested FCS, penicillin (50 U/ml),
streptomycin (50 g/ml), and L-glutamine (4 mM) (all from
Lonza). A stable cell line could be established (usually
within 4–12 weeks) for approximately 50% of the patients
that was subsequently used as a stimulator line for the gen-
eration of tumor-reactive T-cell cultures. Before the initia-
tion of T-cell cultures, the melanoma origin of the used
autologous tumor cells was conWrmed by RT–PCR [13–20]
and they were shown to express at least three of the eleven
melanoma-associated antigens studied (data not shown).
Furthermore, genotyping of HLA alleles was performed
in all melanoma cell lines and corresponding PBMC to con-
Wrm their origin and revealed in addition that none of the
used melanoma cell lines showed complete or partial
genetic loss of HLA alleles. In addition, the surface expres-
sion of HLA class I and class II molecules was assessed by
Xow cytometry using Alexa-648-conjugated W6/32 HLA
class I A/B/C (Serotec, Dusseldorf, Germany) and FITC-
conjugated Bu26 HLA-DR/DP/DQ-speciWc antibodies
(Bio-connect, Huissen, the Netherlands). The samples were
measured on a FACSCalibur and analyzed using CellQuest
Software and showed that HLA class I surface expression
was not downregulated on the cell lines used for the induc-
tion of T cells and that all IFN-stimulated melanoma cells,
except Mel AB and Mel CT, displayed variable surface
expression of HLA class II (data not shown).
Generation and release of T-cell batches for infusion
Tumor-reactive T cells were cultured using a mixed lym-
phocyte tumor cell culture (MLTC) as described [21].
BrieXy, PBMC were isolated from heparinized venous
blood and cryopreserved until use. Approximately 50 mil-
lion PBMC were thawed, washed, counted and resuspended
(1–2 £ 10e6 cells per ml) in T-cell medium; Iscoves MDM
(Lonza) supplemented with 8% heat-inactivated pooled
human serum (Sanquin Bloodbank, Dordrecht, The Nether-
lands), penicillin (50 U/ml), streptomycin (50 g/ml), and
L-glutamine (4 mM) (all GMP-grade from Lonza) and
plated 1 ml per well in a 24-well culture plate. Next, autolo-
gous tumor cells were lethally irradiated (100 Gy) and
resuspended (1 £ 10e5 cells per ml) in T-cell medium. One
milliliter of this tumor cell suspension was added per well
containing PBMC. Human recombinant IL-4 (5 ng/ml,
Cellgenix, Sieversen, Germany and Gentaur, BrusselsCancer Immunol Immunother (2011) 60:953–963 955
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Belgium) was added at day 0. Starting from day 2, low-
dose (150 IU/ml) IL-2 (Aldesleukin, Novartis, Arnhem,
The Netherlands) was added. Culture medium containing
IL-2 was refreshed every 2–3 days. The T cells were cul-
tured for a total of 4 weeks and stimulated weekly with irra-
diated tumor cells as described above. After 4 weeks of
culture, the T-cell batches were evaluated for sterility, phe-
notype, and tumor reactivity before they were released for
infusion. Phenotypic analysis was performed using a FAC-
SCalibur and CellQuest software (BD Pharmingen, San
Jose, CA, USA). T cells were released when they consist of
more than 80% of T cells (CD3+CD4+ and CD3+CD8+) or
NK cells (CD3-CD56+) (All conjugated-mAb were from
BD Pharmingen except CD8-APC from DAKO, Heverlee,
Belgium). In addition, the frequency of Treg
CD4+CD25+FoxP3+ T cells was evaluated in the T-cell
batches using CD4-APC and CD25-FITC mAb (both from
BD Pharmingen) in combination with the human Treg/
FoxP3-PE staining kit (eBiosciences, Vienna, Austria).
Tumor reactivity was assessed by a 51Cr-cytotoxicity assay
[22], and in order to be released for infusion, T cells were
required to speciWcally lyse autologous tumor cells but not
autologous EBV-LCL or PHA blasts (diVerence >10% at
an E/T ratio of 30). Alternatively, tumor reactivity was
assessed by IFN ELISA (Sanquin, Amsterdam, The Neth-
erlands) where T-cell batches were required to secrete
>200 pg/ml IFN in response to autologous tumor cells and
at least twice the amount induced by the negative controls,
i.e., autologous EBV-LCL or PHA blasts [23].
Analysis of T-cell speciWcity, polyclonality, and cytokine 
secretion by multiparameter Xow cytometry
To examine T-cell reactivity, 0.5–1 £ 10e6 T cells were
seeded in a 24-well plate in T-cell medium and stimulated
with 0.5–1 £ 10e6 autologous melanoma cells. After 1 h,
Brefeldin-A (10 g/ml) was added and stimulation was
continued overnight. The next day T cells were har-
vested, and part of the cells were stained with a mix of
antibodies to CD154-PECy5, CD137-APC, CD4-PECy7,
CD8-APCCy7, IFN-FITC, and IL-2-PE (all from BD
Pharmingen) and CD3-PaciWc Blue (DAKO) see [24]. Non-
stimulated T cells or T cells stimulated with PHA (5 g/ml)
served as controls. Responses were considered positive
when the percentage of tumor-stimulated CD154+ and/or
CD137+ T cells was at least three times the medium control
(see Fig 1. of the on-line available supplementary materi-
als).
Polyclonality of the T-cell batches was evaluated by the
anti-IFN-FITC and IL-2-PE Ab by either one of the 8
diVerent mixes of FITC- and/or PE-conjugated anti-
TCRV mAb (BETAmark, Beckman Coulter) as previ-
ously described [25]. The diVerent T-cell clones were
operationally deWned as the percentage of activated tumor-
speciWc CD4+ or CD8+ T cells expressing the same
TCRV-chain, within the population of tumor-speciWcally
activated CD154+ and/or CD137+ T cells, respectively. All
samples were measured on a calibrated LSRII and analyzed
using DIVA software (BD). A TCRV was considered
dominant (>10%), subdominant (3–10%), or minor (<3%)
based on the percentage of tumor-speciWc cells using the
same TCRV [25].
In parallel, T cells were stimulated with autologous mel-
anoma cell lines in the absence of Brefeldin-A, and super-
natant was harvested after 24 h in order to analyze the
cytokine secretion using the human Th1/Th2 cytometric
bead array (BD Pharmingen). T cells stimulated with PHA
(5 g/ml), medium alone, and autologous EBV-LCL or
PHA blasts were included as controls. Antigen-speciWc
cytokine production was deWned by a cytokine concentra-
tion above the cut-oV value (IFN 50 pg/ml; other cyto-
kines 10 pg/ml) and >2 £ the concentration of the medium
control [26].
Statistics
The overall survival was analyzed using Kaplan–Meier and
SPSS version 2.0. The Cox regression could not performed
due to the low patient number, and therefore no conWdence
interval and hazard ratio could be provided. Post hoc statis-
tical analyses were performed to determine potential corre-
lates with clinical responsiveness using the non-parametric
Mann–Whitney Test or Wilcoxon Signed Ranks Test. All p
values are two-sided and are considered signiWcant when
they are less than 0.05.
Results
Patient characteristics
Ten patients with metastatic melanoma were treated with
adoptive transfer of tumor-reactive T cells (ACT) in combi-
nation with low-dose IFN. Two additional patients were
not treated although we obtained tumor-speciWc T cells,
because they continued using chemotherapy or required
dexamethasone to control brain metastasis-related edema,
respectively, and therefore had to be taken of study. The
characteristics of the ten treated patients are shown in
Table 1. All patients had stage IV melanoma with visceral
metastases, including liver, spleen, soft tissue, or bone
metastases, in addition to metastasis in lymph nodes, lungs,
or skin. Prior to ACT, all but one patient (GM) were treated
with radiotherapy and/or chemotherapy (Table 1) and had
progressive disease (PD) refractory to treatment. Seven out
of ten patients had brain metastasis (Table 1). Patients FB956 Cancer Immunol Immunother (2011) 60:953–963
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and GM had high levels of serum LDH (>2 £ upper normal
limit (UNL)) correlating with a bad prognosis and high
tumor load before the start of T-cell infusions, and patient
CT had elevated LDH (i.e., >UNL but <2 £ UNL). Eight
patients completed at least one infusion cycle.
Clinical response
An objective clinical response was observed in two out of
ten patients according to irRC and RECIST, and in three
additional patients, clinical beneWt was manifested as SD.
One patient (BO) exhibits an ongoing complete response
with duration of more than 45 months that was established
after two cycles of ACT (Fig. 1a). Notably, this patient had
an incompletely resected brain metastasis that completely
disappeared after treatment. A second patient (DK) dis-
played an ongoing PR with complete regression of all but
one mesenterial lesion, including a brain lesion, 4 skin
lesions, and 4 LN-lesions. Two patients (EN, see Fig. 1a,
and CT) showed SD (durations of 3+ and 3 months, respec-
tively) but the latter received only one infusion cycle since
treatment had to be discontinued due to a SAE. One other
patient (AB) showed SD with duration of 6 months when
evaluated according to irRC, whereas the duration was
3 month according to RECIST. However, this patient pro-
gressed very slowly resulting in an unexpected long sur-
vival (Fig. 1b; Table 1). Non-responders were deWned as
patients with PD by evaluation of CT and MRI scans
according to RECIST and irRC or by death due to PD.
Adverse events
In half of the patients (5/10), fever (grade 1) was observed
up to 20 h and one patient displayed transient hypertension
(grade 1) after T-cell infusion. No other adverse symptoms
were observed immediately after infusion.
Five out of ten patients suVered from grade 1 (n =4 )  t o
grade 2 (n = 1) psychological symptoms associated with the
administration of IFN (Roferon), resulting in the reduction
and/or discontinuation of the daily dose of IFN given in
patient CT, DK, and JS. One patient (EN) experienced
numbness of Wngers after 7 weeks of IFN treatment. This
disappeared after discontinuation of IFN treatment and
was previously described as a rare side eVect of high-dose
IFN [27]. One patient (CT) developed acral vasculitis with
necrotic-like lesions in her Wngertips without inXammatory
cell inWltrate or microorganisms. Also a folliculitis-like
inXammation of the skin was seen after the Wrst infusion of
the second treatment cycle. Skin biopsies were taken, and
since a role of T cells could not be completely ruled out, the
therapy was discontinued. One responding patient (DK)
experienced grade 1 vitiligo. All serious adverse events are
listed in Table 1 of the on-line available supplementary
materials.
Five out of ten patients showed grade 2 IFN-induced
leucopenia, and six patients had leukocyte counts below
4 £ 10e9 c/l at the start of T-cell infusions (Fig. 1c). The
leukocyte numbers usually remained reduced throughout
the full period that IFN was administered and returned to
Table 1 Patient characteristics
a Metastatic sites at the start of T-cell treatment include lung (Lu), brain (B), subcutaneous (SC), lymph node (LN), liver (Li), muscle (Mu), adrenal
(Ad), spleen (Sp), and bone (Bo) metastasis
b Serum LDH concentration was considered high when it was more than twice the upper limit and elevated when it was above but less then twice
the upper limit
c Prior treatments include radiotherapy (RT) and chemotherapy (CT)
d Best overall response according to response criteria in solid tumors (RECIST 1.0)
e Best overall response according to immune-related response criteria (irRC)
Patient 
ID
Age/sex Status 
before 
therapy
Lesion sitesa LDHb Prior 
therapyc
Infused 
cells (£108)
Best 
overall 
response 
RECISTd
Duration/disease 
stabilization 
(mo)
Best overall 
response 
IrRCe
Duration/disease 
stabilization 
(mo)
Overall 
survival 
(mo)
AB 42/m PD Li Normal RT 19.1 SD 3 iSD 6 47+
BO 35/m PD L, SC, LN, B Normal CT, RT 14.4 CR 45+ iCR 45+ 51+
CT 73/f PD Spl, Bo Elevated RT 14.2 SD 3 iSD 3 15
DK 43/m PD L, SC.LN, B Normal CT, RT 22.5 PR 16+ iPR 16+ 22+
EN 49/f PD B, SC/ID Normal CT 16.9 SD 3+ iSD 3+ 8+
FB 44/f PD Ad, LN, B High CT, RT 1.4 PD n.a. iPD n.a. 1
GM 56/f PD Bo, Li, LN, 
B Lu
High – 2.0 PD n.a. iPD n.a. 1.5
HL 55/m PD Lu, Mu Normal CT 10.6 PD n.a. iPD n.a. 15+
IV 57/m PD B Normal RT 6.3 PD n.a. iPD n.a. 3
JS 68/m PD B, LN, Lu Normal CT, RT 3.9 PD n.a. iPD n.a. 3Cancer Immunol Immunother (2011) 60:953–963 957
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pretreatment values after cessation of IFN injections.
Importantly, the absolute leukocyte count dropped below
the normal number of leukocytes (4 £ 10e9/l) in all patients
which showed a clinical response, whereas it remained
within the normal range of leukocytes 4–12 £ 10e9/L in 4
of the 5 non-responding patients (Fig. 1c) resulting in a sig-
niWcantly lower number of leukocytes in responder patients
compared to non-responder patients (P =0 , 0 1 6 ) .  D i Veren-
tial blood counts showed that especially neutrophil (42%
reduction, range 0–89%) and to a lesser extend lymphocyte
numbers (29% reduction, range 2–56%) were decreased
after IFN treatment and the percentage reduction of the
neutrophil counts correlated with prolonged survival
(P = 0.022; Fig. 1d). Neutrophil counts prior to IFN treat-
ment did not signiWcantly diVer between responder and
non-responder patients (6.9 vs. 4.1 £ 10e9/l, P =0 . 1 5 ) .
The tumor-reactive T cells in the group of clinical 
responders display a strong in vitro expansion rate
PBMC were stimulated 4 times with autologous tumor cells
in vitro. The number of T cells obtained for each patient
diVered and ranged from 5.9 to 465 £ 107, reXecting a
2.1–70-fold increase in cell number.
A comparison of the weekly expansion of T cells of the
groups of responder and non-responder patients clearly
revealed that tumor-stimulated PBMC of the clinical
responders expanded faster than those of the non-respond-
ers, albeit not quite signiWcant (P = 0.056; Fig. 2). Indeed
many more MLTC’s were required to obtain suYcient
numbers of cells to transfuse the non-clinical responders.
The diVerences in expansion were not associated with
the level of HLA class I or II surface expression or the
Fig. 1 Clinical response. a ACT-induced regression of metastatic le-
sions before (upper panels) and after (lower panels) T-cell infusions.
CT scans showing complete regression of two lung lesions obtained
6 month after T-cell infusion in the CR patient BO are depicted in the
left two panels. Regression of a subcutaneous lesion obtained 3 months
after start of the infusions in patient EN is depicted in the right panel.
b Kaplan–Meier plot comparing the overall survival of the responder
and non-responder patients. c IFN treatment induced a mild leuco-
penia. From day 7 before infusion of the Wrst T-cell dose, patients were
treated with 3.10e6 U IFN s.c daily for a total of 12 weeks. The abso-
lute leukocyte count (x10e9/L) measured 1 week after the start of IFN
injections (i.e., day 0) is depicted. The values measured before treat-
ment are shown as a black arrowhead. Absolute leukocyte counts of
the responder patients are depicted as Wlled bars and those of the non-
responders as open bars. The best overall clinical response of the indi-
vidual patients is given in brackets behind the patient ID. Normal leu-
kocyte counts range between 4 and 12 as is indicated by the light gray
area. d The percentage reduction in peripheral neutrophil counts ob-
tained after 7 days of IFN treatment (i.e., day 0) of the non-responder
(open circles) and responder (closed circles) patients correlates with
their overall survival
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pattern of melanoma antigens expressed by the melanoma
cells (data not shown).
Characteristics of infused T cells
All T-cell batches were shown to consist mainly of
CD3+CD4+ and CD3+CD8+ T cells (Fig. 3) but the ratio
of CD8+/CD4+ T cells varied considerably between
patients. The majority of the T cells were CD45RA,
CD62L, and CCR7 negative (eVector memory T cells; data
not shown). T-cell batches from patient DK, GM, HL, and
JS showed expansion of CD3+CD4+ T cells (Fig. 3). T-cell
batches from three of these patients (responder patient DK
and non-responder patients HL and JS) contained a rela-
tively high-frequency CD4+CD25+FoxP3+ T cells, respec-
tively, 9, 6, and 23%, whereas all other batches contained a
mean of only 2.6 § 1.7% of CD4+CD25+FoxP3+ T cells
(data not shown). Furthermore, while in all other patients,
the percentage of CD3+CD8+CD56+ T cells was low
(median 1%, range 0–8%), this was the main subset present
in the T-cell batch of patient CT (not shown).
On average, the T-cell batches induced 19% speciWc
tumor cell lysis in a 51Cr-cytotoxicity assay (at an eVector
to target ratio of 30 and after subtraction of autologous
B-LCL/PHA-blasts lysis) and did not signiWcantly diVer
Fig. 2 Proliferation of T cells during MLTC. T cells were produced by
MLTC using autologous tumor cells as stimulator cells at day 0 and ev-
ery week thereafter. The proliferation was assessed weekly after har-
vesting and counting of viable cell numbers using trypan blue. The
proliferation rate is expressed as fold expansion of cells compared to
cell number at day 0. The median and 25th percentile deviation of the
weekly proliferation rate of responding (Wlled circle, n = 5) and non-
responding (open circle, n = 5) patients are depicted
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between T cells administered to responding and non-
responding patient (Fig. 4). T cells from patient DK and JS
contained mainly CD3+CD4+ T cells and did not show spe-
ciWc lysis in a short-term cytotoxicity assay, but speciWcally
released IFN upon stimulation with the patients’ tumor
cells and not when stimulated with EBV-LCL or PHA
blasts (data not shown).
Based on the tumor-induced expression of the T-cell
activation markers CD154/CD137, the infused T-cell
batches constituted a median of 27.6% (mean 29.3%, range
0–61.1%) tumor-speciWc T cells comprising a median of
2.5% (range 0–22.6) tumor-speciWc CD3+CD4+ T cells
and 16.5% (range 0–57.3%) tumor-speciWc CD3+CD8+ T
cells (Fig. 3). Comparison of the tumor reactivity between
the T-cell batches revealed that there was no signiWcant
diVerence (P = 0.55) in frequencies of tumor-speciWc acti-
vated CD3+CD4+CD154+ or CD3+CD8+CD137+ T cells
administered to responding or non-responding patients.
Assessment of the polyclonality of the tumor-speciWc
T-cell batches, operationally deWned as the cohort of CD4+
or CD8+ T cells expressing the same TCRV-chain within
the population of tumor-activated CD154+ and/or CD137+
T cells, revealed on average the involvement of 8 TCRV
families (range 0–15) indicating that the infused tumor-spe-
ciWc T-cell population is highly polyclonal. No signiWcant
Fig. 4 Reactivity of infused T cells. The speciWc reactivity of the
T-cell batches was analyzed by cytotoxicity assay. EVector T cells
were added in increasing ratios to radioactively 51Cr-labeled target
cells (E/T) and incubated for 4 h at 37°C. SpeciWc lysis of target cells
was calculated after measuring the 51Cr release as described [22]. The
percentage-speciWc lysis of autologous melanoma cells (black bars)
and corresponding PHA blasts or EBV-LCL control cells (white bars)
at diVerent E/T ratios is depicted. The patient ID of the diVerent T-cell
batches is given in the upper right corner of the corresponding graphs.
Results for the responder and non-responder patients are shown in the
left and right panels, respectively
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Table 2 Polyclonality of tumor-reactive T cells
T cells were stimulated overnight with autologous tumor cells, and the
frequencies of cells expressing a speciWc TCRV were analyzed in the
populations of CD3+CD4+ and CD3+CD8+ T cells that expressed the
activation marker CD154 or CD137, respectively. Frequencies of T
cells that express a speciWc TCRV were calculated after subtraction
of background frequencies obtained with medium alone. The number
of subdominant (frequency between 3 and 10%) and dominant
(frequency >10%) TCRV families represented within the tumor-
speciWc T-cell fraction is depicted
The best overall clinical response of the individual patients is given in
brackets behind the patient ID
Patient CD154+CD4+ T cells CD137+CD8+ T cells
Subdominant Dominant Subdominant Dominant
AB (SD) 0 0 4 0
BO (CR) 7 1 5 2
CT (SD) 0 0 0 0
DK (PR) 8 0 5 0
EN (SD) 10 1 0 2
FB (PD 0 0 0 0
GM (PD) 0 0 3 1
HL (PD) 5 1 5 2
IV (PD) 1 3 2 0
JS (PD) 8 1 0 0960 Cancer Immunol Immunother (2011) 60:953–963
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diVerences were observed in this respect between clinical
responders and non-responders (Table 2).
The polyfunctionality of the tumor-speciWc T cells, deW-
ned by the percentage of cells secreting IFN and/or IL-2
within the fraction of tumor-speciWc T cells (see Fig. 2 of
the supplementary materials available on-line), was not
overtly diVerent between the T-cell batches from the groups
of clinically responding and non-responding patients. How-
ever, the cytokine proWle produced by the infused T cells
varied from predominantly Th1-type cytokines (IFN, IL-2
and TNF) in four clinically responding patients to pre-
dominantly Th2 cytokines (IL-4, IL-5 and IL-10, patient IV
and JS), a mix of Th1 and Th2 cytokines (patient HL) or no
cytokines at all (patient FB and GM) in patients without a
clinical response (Fig. 5). All together these data suggest
that a predominant Th1 cytokine proWle is beneWcial for the
clinical outcome.
Discussion
The results of this phase I/II study clearly demonstrate that
adoptive transfer of PBMC-derived tumor-speciWc T cells
in combination with low-dose INF is feasible and safe and
can induce a disease control (CR, PR, and SD) in 50% of
the treated patients displaying progressive metastatic mela-
noma before treatment without any major adverse events
related to the infusion of T cells. Analyses of several diVer-
ent immune-related parameters, which are discussed in
more detail below, resulted in a number of hypotheses that
could explain clinical reactivity or the lack thereof. All
together, these data warrant the conduct of a controlled
clinical trial to conWrm or reject our current observations.
All responding patients experienced an IFN -induced
mild and transient leucopenia including both reduced
lymphocyte and in particular neutrophil numbers. Interest-
ingly, high peripheral neutrophil numbers are described to
be an independent prognostic factor for worse outcome of
IL-2-based therapy in melanoma patients [28]. Here, we
observe that the level of neutrophil reduction after IFN-
conditioning correlates with increased survival and that all
clinically responding patients display a clear reduction in
peripheral neutrophil numbers after IFN treatment. Nota-
bly, there was no diVerence in neutrophil numbers between
these groups before treatment that could explain a diVer-
ence in survival. Since expansion of IL-10-secreting immu-
nosuppressive neutrophils has recently been shown to
correlate with disease progression in melanoma [29], the
observed IFN-mediated reduction in neutrophil numbers
may have resulted in lower IL-10 levels but unfortunately
this could not be tested in our current patient group because
we did not obtain serum of all patients prior to therapy. A
recent study in melanoma patients reported the reduction in
regulatory T cells (Treg) following high-dose IFN treat-
ment [30]. Whether the leucopenia observed in our study
after a much lower dose of IFN treatment also reduces the
frequency of Treg or creates space for infused T cells and/or
induces homeostatic cytokines IL-7 and IL-15, as has been
Fig. 5 Th1 and Th2 cytokine 
proWle of T cells used for infu-
sion. T cells were stimulated 
with autologous tumor cells 
overnight, and the supernatant 
was analyzed for the production 
of Th1 (IFN, IL-2 and TNF) 
and Th2 (IL-10, 4 and 5) cyto-
kines. The cytokine production 
after subtraction of background 
production after culture in medi-
um alone is depicted for re-
sponder (black bars) and non-
responder (white bars) patients, 
respectively. The best overall 
clinical response of the individ-
ual patients is given in brackets 
behind the patient ID. ND is not 
detectable
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suggested as mechanism to explain the beneWcial eVect of
other lymphodepleting-conditioning regimens [2], remains
to be elucidated. Although IFN is a pleiotropic cytokine
and its use may contribute to the eventual clinical eVect via
a variety of pathways, a direct inhibitory eVect of IFN on
the tumor is unlikely since single-agent IFN treatment is
only eVective in much higher doses than the low dose used
in our study, which was proven to be not eVective in phase
I/II studies [31, 32].
To unravel potential mechanisms underlying the clini-
cal responsiveness of patients, we performed a detailed
characterization of the infused T-cell batches and
observed that the expansion rate of T cells during the pro-
duction phase was higher for cells infused in patients with
a clinical response. This cannot be attributed to a reduced
frequency of tumor-speciWc T cells in the PBMC or lack
of antigen expression on autologous cell lines used to
obtain the T-cell batches, since tumor-speciWc polyclonal
T-cell populations were obtained in all patients. Whether
the reduced expansion rate of T cells infused to non-
responding patients is due to expression and/or secretion
of immunosuppressive factors by their autologous tumor
cells is subject of our current investigations. Alterna-
tively, the reduced proliferation in the non-responding
patients may be due to an intrinsic lack of proliferative
capacity of their PBMC. Indeed, the proliferative capacity
of ex vivo expanded tumor-inWltrating lymphocytes has
been associated with tumor regression and has been
linked to telomere length in these T cells [33]. The
reduced proliferation of T cells may also be due to the
selective expansion of Treg, since at least in some cases
(patient HL and JS), relatively high frequencies of
CD4+CD25+FoxP3+ T cells were detected in the T-cell
batches. Indeed, the accumulation of Treg in peripheral
blood and locally in the tumor environment and metastatic
lymph nodes of melanoma patients has previously been
associated with impaired T-cell responsiveness [34] and
as such supports this idea. However, functional studies are
required to appreciate their suppressive role during the
mixed tumor T-cell cultures in vitro.
The stimulation of patients’ PBMC with autologous
tumor cells, expressing the full spectrum of relevant HLA
molecules and tumor antigens, leads to expansion of poly-
clonal CD4+ as well as CD8+ T cells, which may contrib-
ute to the current success. Although a recent case report
shows that treatment of a melanoma patient with clonal
NY-ESO-1-speciWc CD4+ T cells can be successful [35],
we aim at infusion of polyclonal T cells, thus preventing
the appearance of antigen-loss variants frequently found
after transfer of single-antigen-speciWc T cells [36,  37].
Since polyclonal tumor-reactive T cells are infused in all
patients but the clinical response does not merely correlate
to the percentage or ratio of speciWc CD8+ versus CD4+ T
cells, we conclude that the presence of a broad repertoire of
tumor-reactive T cells by itself is not suYcient to induce a
clinical eVect but relies on other factors including their
functional activity. Our patient number is too small to reach
signiWcance, but our results are in line with previous obser-
vations [38–40], indicating that infusion of T cells that pre-
dominantly produce Th1 cytokines results in a better
clinical outcome compared to infusion of T cells that pro-
duce mainly Th2 cytokines or no Th1/Th2 cytokines at all
and that the presence of both tumor-speciWc Th1 cells and
CTL mediates an eVective anti-tumor response [41].
In summary, the adoptive transfer of polyclonal tumor-
speciWc T cells obtained after stimulation of PBMC with
autologous tumor cells in combination with low-dose IFN
can result in durable clinical responses in stage IV mela-
noma patients supporting the idea to explore IFN as an
alternative conditioning regimen and cytokine for ACT tri-
als. Although the use of IFN also comes with some side
eVects, including the beneWcial leukopenia and controllable
psychological symptoms, it is far less toxic than high-dose
IL-2, commonly used to support transferred T cells.
The clinical responses reported here are associated with
IFN-induced lympho- and neutropenia and the prolifera-
tive capacity as well as the Th1/Th2 cytokine proWle of the
T cells used for infusion, underscoring the importance of
measuring parameters that are associated with clinical reac-
tivity of the infused T-cell batches to fully appreciate their
in vivo eVectiveness. Eventual combination of this
approach with other treatment options may even further
enhance the clinical outcome. One possibility is the com-
bined use of ACT/IFN with ipilimumab or negative
immunoregulatory human cell surface receptor PD-1 (pro-
grammed death-1). These immune activating antibodies
may result in further in vivo expansion of tumor-speciWc T
cells and improved clinical eVect after ACT/IFN.
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